Twist Bioscience logo

Twist Bioscience

Growth

Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, pharma, and AgBio.

Best for: Synthetic Biology & DNA Synthesis
16
AI Score
Grade D↑ Trending
AI Visibility Score (Beta)
Life Sciences & BioTechSynthetic Biology & DNA SynthesisWebsiteUpdated April 2026

Brand Intelligence Graph

Capabilities
Synthetic Biology & DNA Synthesis

Company Overview

About Twist Bioscience

Twist Bioscience was founded in 2013 in San Francisco by Emily Leproust, Bill Banyai, and Bill Peck, pioneering a silicon-based DNA synthesis platform that writes synthetic DNA at a fraction of the cost and error rate of conventional methods. By printing DNA on silicon wafers using a semiconductor-like process, Twist dramatically reduced the cost of synthetic genes from hundreds to single-digit dollars per gene, democratizing access to DNA writing for the life sciences.

Business Model & Competitive Advantage

Twist serves over 3,000 customers across biopharmaceuticals, academic research, agriculture, and industrial biotechnology, offering synthetic genes, variant libraries, DNA data storage oligos, and antibody libraries for drug discovery. The company reported $376.6 million in FY2025 revenue, up 20% from $313 million in FY2024, driven by strong growth in its biopharma and drug discovery segments. Twist also operates a growing antibody drug discovery business, providing synthetic antibody libraries that power next-generation therapeutic discovery programs.

Competitive Landscape 2025–2026

Twist has a supply agreement with Ginkgo Bioworks for synthetic DNA to fuel Ginkgo's cell engineering platform, revised in 2025. The company is executing toward profitability, with improving gross margins as manufacturing scale increases. Its silicon-based DNA synthesis platform positions it as critical infrastructure for the emerging bioeconomy, synthetic biology, and DNA data storage industries.

Founded
2013
Revenue
$376M
Curated content • Fact-checked and verified

Key Differentiators

Growth Stage

Twist Bioscience has achieved $376M in revenue, demonstrating strong product-market fit.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

16
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Regeneron logo

Regeneron

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Vivtex logo

Vivtex

BioTech
HealthtechB2b

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall

For Twist Bioscience

Claim This Profile

Are you from Twist Bioscience? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Twist Bioscience Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Twist Bioscience vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →